D. E. Shaw & Co., Inc. Adc Therapeutics Sa Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Adc Therapeutics Sa stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 284,243 shares of ADCT stock, worth $534,376. This represents 0.0% of its overall portfolio holdings.
Number of Shares
284,243Holding current value
$534,376% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding ADCT
# of Institutions
80Shares Held
55.1MCall Options Held
82.7KPut Options Held
31.5K-
Redmile Group, LLC San Francisco, CA15.7MShares$29.5 Million3.23% of portfolio
-
Prosight Management, LP Dallas, TX9.64MShares$18.1 Million8.15% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.53MShares$8.52 Million0.34% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$6.68 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.04MShares$5.72 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $146M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...